Antidepressant Therapy for Preeclampsia

This trial explores whether the common antidepressant Paroxetine Hydrochloride can improve blood vessel health in women who experienced preeclampsia during pregnancy and may also have depression. Preeclampsia causes high blood pressure and other issues during pregnancy and may increase the risk of heart disease and depression later on. The trial will test the medicine's effect on blood flow in the skin, using a heating method to observe blood vessel response. Women who had a baby 12 weeks to 5 years ago and either had preeclampsia, depression, or neither might be suitable for this study. As an Early Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

Studies have shown mixed results regarding the safety of paroxetine hydrochloride, the treatment under investigation in this trial. Research indicates that using paroxetine during the first trimester of pregnancy might slightly increase the risk of heart defects in babies, from a typical 1% to about 2%. However, many studies have found no major link between paroxetine and birth defects beyond this.

Paroxetine is an antidepressant classified as an SSRI (selective serotonin reuptake inhibitor), generally considered safe for other uses. Nonetheless, evidence suggests that using paroxetine during pregnancy could increase the chance of high blood pressure, sometimes related to preeclampsia.

As for ascorbic acid, or Vitamin C, studies show it doesn't reduce the risk of preeclampsia when used alone. High doses are not recommended during pregnancy to prevent problems. However, Vitamin C is generally safe in regular amounts and is important for overall health.

Researchers are excited about this trial because it explores how paroxetine hydrochloride, traditionally an antidepressant, might affect blood flow in women with preeclampsia. Unlike standard treatments for preeclampsia, which typically focus on managing blood pressure, this study investigates paroxetine's impact on vascular responses. By examining how this drug influences nitric oxide pathways and skin blood flow, the trial aims to uncover potential new ways to manage or even treat preeclampsia, a condition with limited therapeutic options. This innovative approach could lead to breakthroughs in how we understand and address preeclampsia using a drug with a known safety profile.

Research shows that paroxetine, a medication for depression, helps by boosting serotonin levels, easing depression and anxiety symptoms. Early studies suggest that women who took paroxetine after experiencing preeclampsia had healthier blood vessels, indicating potential heart health benefits. In this trial, participants will receive paroxetine alone, ascorbic acid alone, or a combination of both. Past studies have shown that Vitamin C, also known as ascorbic acid, has not been effective in preventing preeclampsia. It is important to note that using paroxetine with Vitamin C has not been proven to prevent preeclampsia. However, the potential benefit of paroxetine on blood vessel health after preeclampsia remains an interesting area of research.⁶⁷⁸⁹¹⁰